Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 46.04B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 32.41M |
| Shares Out | n/a |
| EPS (ttm) | 0.25 |
| PE Ratio | 1,420.70 |
| Forward PE | 43.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18 |
| Average Volume | 134 |
| Open | 464.01 |
| Previous Close | 471.11 |
| Day's Range | 458.26 - 468.29 |
| 52-Week Range | 209.75 - 500.21 |
| Beta | n/a |
| RSI | 58.37 |
| Earnings Date | Feb 20, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
Alnylam Pharmaceuticals Announces Changes to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of tw...
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M
Disclosed in a recent SEC filing on December 1, Greenstreet, Chief Executive Officer at Alnylam Pharmaceuticals (NASDAQ: ALNY), made a noteworthy transaction involving the exercise of company stock o...
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing
Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.
American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarte...
ALNY Quantitative Stock Analysis
Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Quantitative Momentum Investor model based on the...
What's Going On With Alnylam Stock On Friday?
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.
What's Going On With Alnylam Stock On Friday?
Alnylam Pharmaceuticals, Inc . (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement. ALNY is demonstrating bullish strength. See what is driving the movement here. P...
Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review
The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were...
Validea Detailed Fundamental Analysis - ALNY
Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Quantitative Momentum Investor model based on the...
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 17.12% on an annualized basis producing an average annual return of 29.2%. Currently, Alnylam Pharmaceutic...
UK's drug-cost watchdog recommends Alnylam's heart disease drug
The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the compa...
High-Flying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double
Alnylam stock is holding its 50-day moving average as it seeks to get back to its buy point of 484.21.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM ESTCompany ParticipantsYvonne Greenstreet - CEO...
Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALNY) | ALNY Stock News
Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALNY) | ALNY Stock News
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money
Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM ESTCompany ParticipantsJeffrey Poulton - CFO &...
Alnylam (ALNY) Reports Positive Results from HELIOS-B Phase 3 Study
Alnylam (ALNY) Reports Positive Results from HELIOS-B Phase 3 Study
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study...
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 20.5%. Currently, Alnylam Pharmaceutic...
What Does the Market Think About Alnylam Pharmaceuticals Inc?
Alnylam Pharmaceuticals Inc's (NYSE: ALNY) short interest as a percent of float has risen 13.65% since its last report. According to exchange reported data, there are now 3.99 million shares sold sho...
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p...
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Royalty Pharma (RPRX) Secures $310 Million Royalty Interest in Alnylam's AMVUTTRA
Royalty Pharma (RPRX) Secures $310 Million Royalty Interest in Alnylam's AMVUTTRA